{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:19:43Z","timestamp":1778599183125,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.cmi.2020.01.014","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T02:32:14Z","timestamp":1579573934000},"page":"818-823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Elimination of hepatitis C in Europe: can WHO targets be achieved?"],"prefix":"10.1016","volume":"26","author":[{"given":"M.","family":"Mati\u010di\u010d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario U.","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.01.014_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib2","series-title":"Global hepatitis report","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.cmi.2020.01.014_bib3","series-title":"Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000\u20132016","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.cmi.2020.01.014_bib4","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.cmi.2020.01.014_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2014.07.015","article-title":"Can hepatitis C be eradicated in the United States?","volume":"110","author":"Edlin","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2020.01.014_bib6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.01.014_bib7","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.cmi.2020.01.014_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1411-9","article-title":"The case for a universal hepatitis C vaccine to achieve hepatitis C elimination","volume":"17","author":"Scott","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2020.01.014_bib9","series-title":"Staged phase I\/II hepatitis C prophylactic vaccine NCT01436357","year":"2019"},{"key":"10.1016\/j.cmi.2020.01.014_bib10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.01.014_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cmi.2020.01.014_bib12","first-page":"S179","article-title":"The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"68","author":"Trickey","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib13","article-title":"European monitoring centre for drugs and drug","year":"2019","journal-title":"Eur Drug Rep"},{"key":"10.1016\/j.cmi.2020.01.014_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-019-0528-6","article-title":"Epidemiology and management of hepatitis C virus infections in immigrant populations","volume":"8","author":"Coppola","year":"2019","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.cmi.2020.01.014_bib15","series-title":"Guidelines on hepatitis B and C testing: policy brief","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.cmi.2020.01.014_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurpub\/ckp001","article-title":"Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection","volume":"19","author":"Sroczynski","year":"2009","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.cmi.2020.01.014_bib17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jval.2019.06.006","article-title":"Cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the national health service health check program in England","volume":"22","author":"Williams","year":"2019","journal-title":"Value Heal"},{"key":"10.1016\/j.cmi.2020.01.014_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S2468-1253(18)30268-1","article-title":"One step closer to elimination of hepatitis C in Egypt","volume":"3","author":"Esmat","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2019.06.026","article-title":"Excellence in viral hepatitis elimination \u2013 lessons from Georgia","volume":"71","author":"Averhoff","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/joim.12740","article-title":"Treatment as Prevention for Hepatitis C (TraP Hep C) \u2013 a nationwide elimination programme in Iceland using direct-acting antiviral agents","volume":"283","author":"Olafsson","year":"2018","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cmi.2020.01.014_bib21","series-title":"Eliminating hepatitis costs money, but saves even more","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.cmi.2020.01.014_bib22","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1016\/S2214-109X(19)30272-4","article-title":"Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016\u201330","volume":"7","author":"Tordrup","year":"2019","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.cmi.2020.01.014_bib23","series-title":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.cmi.2020.01.014_bib24","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1016\/S2214-109X(19)30266-9","article-title":"Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis","volume":"7","author":"Simmons","year":"2019","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.cmi.2020.01.014_bib25","series-title":"Global medicines use in 2020: outlook and implications","year":"2015"},{"key":"10.1016\/j.cmi.2020.01.014_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep4.1028","article-title":"Hepatitis C virus infection in children and adolescents","volume":"1","author":"Squires james","year":"2017","journal-title":"Hepatol Commun 17AD"},{"key":"10.1016\/j.cmi.2020.01.014_bib27","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir\u2013sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6\u201311","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2020.01.014_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0207226","article-title":"Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?","volume":"13","author":"Madden","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2020.01.014_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/joim.12972","article-title":"We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade","volume":"286","author":"Lazarus","year":"2019","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cmi.2020.01.014_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","volume":"3","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-018-1162-z","article-title":"Pathways to ensure universal and affordable access to hepatitis C treatment","volume":"16","author":"Douglass","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2020.01.014_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz714","article-title":"The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination","author":"Safreed-Harmon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.01.014_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.01.014_bib34","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/S0168-8278(16)01643-3","article-title":"HCV Reinfection incidence and outcomes among HIV Infected MSM in western Europe","volume":"64","author":"Martin","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2020.01.014_bib37","article-title":"Approaches for simplified HCV diagnostic algorithms","volume":"21","author":"Fourati","year":"2018","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.cmi.2020.01.014_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COH.0000000000000370","article-title":"Diagnosis of viral hepatitis","volume":"12","author":"Easterbrook","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cmi.2020.01.014_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-2988-x","article-title":"Hepatitis B\/C in the countries of the EU\/EEA: a systematic review of the prevalence among at-risk groups","volume":"18","author":"Falla","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2020.01.014_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011821","article-title":"Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations","volume":"6","author":"Coward","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2020.01.014_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.cmi.2020.01.014_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2012.08.024","article-title":"All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study","volume":"58","author":"Kielland","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","article-title":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","volume":"71","author":"Mac\u00edas","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2018.09.030","article-title":"Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia","volume":"70","author":"Iversen","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12954-019-0303-9","article-title":"Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries","volume":"16","author":"Maticic","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.cmi.2020.01.014_bib46","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-019-4284-9","article-title":"Prevalence of hepatitis C infection among the general population and high-risk groups in the EU\/EEA: a systematic review update","volume":"19","author":"Han","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2020.01.014_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0208107","article-title":"Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection \u2013 a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis","volume":"13","author":"Werner","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2020.01.014_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0163488","article-title":"Cost-effectiveness of hepatitis c treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, The Netherlands","volume":"11","author":"Van Santen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2020.01.014_bib49","article-title":"Substantial decline in acute HCV infections among Dutch HIV+ MSM after DAA roll out","volume":"2017","author":"Boerekamps","year":"2017","journal-title":"CROI"},{"key":"10.1016\/j.cmi.2020.01.014_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/cid\/ciy547","article-title":"High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus\/hepatitis c virus-coinfected men who have sex with men","volume":"68","author":"Braun","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.01.014_bib51","article-title":"Fall in HCV incidence in HIV+ MSM in London following wider access to DAA therapy","volume":"2019","author":"Garvey","year":"2019","journal-title":"CROI"},{"key":"10.1016\/j.cmi.2020.01.014_bib52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","article-title":"Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees","volume":"388","author":"Dolan","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.01.014_bib53","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.2105\/AJPH.2014.302546","article-title":"A\u00a0comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991","volume":"105","author":"Spaulding","year":"2015","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cmi.2020.01.014_bib54","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/add.13783","article-title":"Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland","volume":"112","author":"Stone","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.cmi.2020.01.014_bib55","article-title":"Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe 11 Medical and Health Sciences 1117 public health and health services","volume":"19","author":"St\u00f6ver","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cmi.2020.01.014_bib56","article-title":"Microenvironment eradication of hepatitis C: a novel treatment paradigm","volume":"1\u201310","author":"Cuadrado","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2020.01.014_bib57","series-title":"Marked reduction of hepatitis C prevalence in the prison setting during 2nd year of TraP HepC (Treatment as Prevention for Hepatitis C) program in Iceland","author":"Fridriksdottir","year":"2018"},{"key":"10.1016\/j.cmi.2020.01.014_bib58","series-title":"Epidemiological assessment of hepatitis B and C among migrants in the EU\/EEA","year":"2016"},{"key":"10.1016\/j.cmi.2020.01.014_bib59","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jhep.2017.12.013","article-title":"Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020","volume":"68","author":"Scott","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2020.01.014_bib61","article-title":"Hepatitis C: is eradication possible?","volume":"1\u201311","author":"Lombardi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cmi.2020.01.014_bib62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(18)30462-8","article-title":"Tackling hepatitis C\u2014Pakistan\u2019s road to success","volume":"391","author":"Moin","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.01.014_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026726","article-title":"Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study","volume":"9","author":"Chen","year":"2019","journal-title":"BMJ Open"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20300392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20300392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:24:59Z","timestamp":1761117899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20300392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1198743X20300392"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.01.014","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elimination of hepatitis C in Europe: can WHO targets be achieved?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}